D006086DisordersC20.45215180.987387Graft vs Host DiseaseFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonWake Forest School of MedicineFrankMariniFrank C. Marini PhD36.08943500000000-80.268632000000001107Marini, FrankProfessorGiuseppeOrlandoGiuseppe Orlando MD, PhD36.08959100000000-80.268599000000001226Orlando, GiuseppeAssociate Professor27456485McIver ZA, Grayson JM, Coe BN, Hill JE, Schamerhorn GA, Ohulchanskyy TY, Linder MK, Davies KS, Weiner RS, Detty MRJournal of immunology (Baltimore, Md. : 1950)McIver ZA, Grayson JM, Coe BN, Hill JE, Schamerhorn GA, Ohulchanskyy TY, Linder MK, Davies KS, Weiner RS, Detty MR. Targeting T Cell Bioenergetics by Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells To Prevent Graft-versus-Host Disease. J Immunol. 2016 09 01; 197(5):1631-41.J Immunol2016-07-25T00:00:002016Targeting T Cell Bioenergetics by Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells To Prevent Graft-versus-Host Disease.VijayGorantlaVijay S. Gorantla MD, PhD36.08943500000000-80.268632000000002181Gorantla, VijayProfessor29382954Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MRBone marrow transplantationTurcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, Horowitz MM, Knight JM, Verneris MR. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant. 2018 07; 53(7):932-937.Bone Marrow Transplant2018-01-30T00:00:002018Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation.30205231Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, Dueck AC, Mascarenhas JO, Hoffman RBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationGupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, Dueck AC, Mascarenhas JO, Hoffman R. Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant. 2019 02; 25(2):256-264.Biol Blood Marrow Transplant2018-09-08T00:00:002018Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study.24Assistant Professor22Associate ProfessorRaviPaluriRavi K. Paluri MD, MPH2572Paluri, RaviAssociate Professor25599169Gul Z, Van Meter E, Abidi M, Ditah I, Abdul-Hussein M, Deol A, Ayash L, Lum LG, Waller EK, Ratanatharathorn V, Uberti J, Al-Kadhimi ZBone marrow transplantationGul Z, Van Meter E, Abidi M, Ditah I, Abdul-Hussein M, Deol A, Ayash L, Lum LG, Waller EK, Ratanatharathorn V, Uberti J, Al-Kadhimi Z. Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort. Bone Marrow Transplant. 2015 Mar; 50(3):432-7.Bone Marrow Transplant2015-01-19T00:00:002015Low blood lymphocyte count at 30 days post transplant predicts worse acute GVHD and survival but not relapse in a large retrospective cohort.Internal Medicine, Hematology & OncologyOtolaryngologySurgery, TransplantWake Forest Institute for Regenerative MedicineMichaelBrennanMichael T. Brennan DDS, MHS3193Brennan, MichaelClinical Professor34288026Jamy O, Innis-Shelton R, Bal S, Paluri R, Salzman D, Di Stasi A, Costa L, Meredith R, Lamb L, Minagawa K, Mineishi S, Saad AAmerican journal of hematologyJamy O, Innis-Shelton R, Bal S, Paluri R, Salzman D, Di Stasi A, Costa L, Meredith R, Lamb L, Minagawa K, Mineishi S, Saad A. Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation. Am J Hematol. 2021 Oct 01; 96(10):E396-E398.Am J Hematol2021-07-31T00:00:002021Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation.true1Associate ProfessorAssociate Professortrue1Clinical ProfessorClinical Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessor0.5999250.020012515research area of0.8361420.04396238subject area for